688247 宣泰医药
交易中 02-09 10:22:17
资讯
新帖
简况
宣泰医药（688247）披露2025年年度业绩预告，1月29日股价下跌1.24%
证券之星 · 01-29
宣泰医药（688247）披露2025年年度业绩预告，1月29日股价下跌1.24%
宣泰医药(688247.SH)发预减，预计2025年归母净利润4507万元至5408万元，同比下降57.65%至64.71%
智通财经 · 01-29
宣泰医药(688247.SH)发预减，预计2025年归母净利润4507万元至5408万元，同比下降57.65%至64.71%
每周股票复盘：宣泰医药（688247）注射用硫酸艾沙康唑获批上市
证券之星 · 01-11
每周股票复盘：宣泰医药（688247）注射用硫酸艾沙康唑获批上市
宣泰医药(688247.SH)：注射用硫酸艾沙康唑获得国家药品监督管理局批准
智通财经 · 01-06
宣泰医药(688247.SH)：注射用硫酸艾沙康唑获得国家药品监督管理局批准
宣泰医药(688247.SH)拟推2025年限制性股票激励计划
智通财经 · 2025-12-25
宣泰医药(688247.SH)拟推2025年限制性股票激励计划
宣泰医药（688247）披露募投项目延期公告，12月12日股价下跌0.5%
证券之星 · 2025-12-12
宣泰医药（688247）披露募投项目延期公告，12月12日股价下跌0.5%
宣泰医药（688247）披露公司产品续约纳入国家医保目录，12月08日股价上涨0.39%
证券之星 · 2025-12-08
宣泰医药（688247）披露公司产品续约纳入国家医保目录，12月08日股价上涨0.39%
11月26日宣泰医药现346.5万元大宗交易
证券之星 · 2025-11-26
11月26日宣泰医药现346.5万元大宗交易
每周股票复盘：宣泰医药（688247）股东减持8.7万股至持股4.98%
证券之星 · 2025-11-09
每周股票复盘：宣泰医药（688247）股东减持8.7万股至持股4.98%
11月4日宣泰医药发布公告，股东减持8.7万股
证券之星 · 2025-11-04
11月4日宣泰医药发布公告，股东减持8.7万股
宣泰医药(688247)9月30日股东户数0.78万户，较上期减少3.25%
证券之星 · 2025-10-30
宣泰医药(688247)9月30日股东户数0.78万户，较上期减少3.25%
宣泰医药(688247.SH)发布前三季度业绩，归母净利润6346万元，同比下降31.45%
智通财经 · 2025-10-30
宣泰医药(688247.SH)发布前三季度业绩，归母净利润6346万元，同比下降31.45%
宣泰医药最新公告：奥拉帕利片拟中选第十一批全国药品集中采购
证券之星 · 2025-10-29
宣泰医药最新公告：奥拉帕利片拟中选第十一批全国药品集中采购
10月22日宣泰医药发布公告，股东减持313.1万股
证券之星 · 2025-10-22
10月22日宣泰医药发布公告，股东减持313.1万股
宣泰医药（688247）披露关于变更签字注册会计师的公告，10月21日股价上涨2.86%
证券之星 · 2025-10-21
宣泰医药（688247）披露关于变更签字注册会计师的公告，10月21日股价上涨2.86%
宣泰医药(688247.SH)：西格列汀二甲双胍缓释片获美国FDA批准文号
智通财经 · 2025-10-20
宣泰医药(688247.SH)：西格列汀二甲双胍缓释片获美国FDA批准文号
每周股票复盘：宣泰医药（688247）每股派息0.025元（含税）
证券之星 · 2025-10-19
每周股票复盘：宣泰医药（688247）每股派息0.025元（含税）
宣泰医药公布国际专利申请：“恩扎卢胺药物组合物及其制备方法和用途”
证券之星 · 2025-10-18
宣泰医药公布国际专利申请：“恩扎卢胺药物组合物及其制备方法和用途”
宣泰医药（688247）披露2025年半年度权益分派实施公告，10月14日股价下跌0.96%
证券之星 · 2025-10-14
宣泰医药（688247）披露2025年半年度权益分派实施公告，10月14日股价下跌0.96%
宣泰医药（688247）股东南京市栖和创业投资合伙企业(有限合伙)质押1000万股，占总股本2.21%
证券之星 · 2025-10-10
宣泰医药（688247）股东南京市栖和创业投资合伙企业(有限合伙)质押1000万股，占总股本2.21%
加载更多
公司概况
公司名称：
上海宣泰医药科技股份有限公司
所属行业：
医药制造业
上市日期：
2022-08-25
主营业务：
上海宣泰医药科技股份有限公司的主营业务是高端仿制药研发与产业化及创新药CRO/CMO一体化服务。公司的主要产品是泊沙康唑肠溶片、美沙拉秦肠溶缓释片、马昔腾坦片、西格列汀二甲双胍缓释片、达格列净二甲双胍缓释片。
发行价格：
9.37
{"stockData":{"symbol":"688247","market":"SH","secType":"STK","nameCN":"宣泰医药","latestPrice":10.44,"timestamp":1770603737000,"preClose":10.41,"halted":0,"volume":896268,"delay":0,"changeRate":0.0029,"floatShares":453000000,"shares":453000000,"eps":0.2175,"marketStatus":"交易中","change":0.03,"latestTime":"02-09 10:22:17","open":10.47,"high":10.52,"low":10.41,"amount":9364500,"amplitude":0.0106,"askPrice":10.46,"askSize":310,"bidPrice":10.44,"bidSize":778,"shortable":0,"etf":0,"ttmEps":0.2175,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1770607800000},"marketStatusCode":2,"adr":0,"adjPreClose":10.41,"symbolType":"stock_kcb","openAndCloseTimeList":[[1770600600000,1770607800000],[1770613200000,1770620400000]],"highLimit":11.45,"lowLimit":9.37,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":453340000,"isCdr":false,"pbRate":3.61,"roa":"--","peRate":48,"roe":"4.9%","epsLYR":0.28,"committee":0.500539,"marketValue":4733000000,"turnoverRate":0.002,"status":0,"floatMarketCap":4733000000},"requestUrl":"/m/hq/s/688247","defaultTab":"news","newsList":[{"id":"2607707044","title":"宣泰医药（688247）披露2025年年度业绩预告，1月29日股价下跌1.24%","url":"https://stock-news.laohu8.com/highlight/detail?id=2607707044","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607707044?lang=zh_cn&edition=full","pubTime":"2026-01-29 17:40","pubTimestamp":1769679603,"startTime":"0","endTime":"0","summary":"截至2026年1月29日收盘，宣泰医药报收于10.37元，较前一交易日下跌1.24%，最新总市值为47.01亿元。该股当日开盘10.55元，最高10.56元，最低10.3元，成交额达3450.28万元，换手率为0.73%。近日，上海宣泰医药科技股份有限公司披露《2025年年度业绩预告》。公告显示，公司预计2025年年度实现营业收入39,383.00万元至47,260.00万元，同比减少7.63%至23.02%；归属于母公司所有者的净利润为4,507.00万元至5,408.00万元，同比减少57.65%至64.71%；扣除非经常性损益的净利润为2,961.00万元至3,553.00万元，同比下降68.82%至74.02%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012900030024.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688247","BK0239"],"gpt_icon":0},{"id":"2607707808","title":"宣泰医药(688247.SH)发预减，预计2025年归母净利润4507万元至5408万元，同比下降57.65%至64.71%","url":"https://stock-news.laohu8.com/highlight/detail?id=2607707808","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607707808?lang=zh_cn&edition=full","pubTime":"2026-01-29 17:26","pubTimestamp":1769678806,"startTime":"0","endTime":"0","summary":"智通财经APP讯，宣泰医药(688247.SH)发布公告，公司预计2025年年度实现归属于母公司所有者的净利润4507万元至5408万元，与上年同期相比，将减少7,362.06万元至8,263.06万元，同比下降57.65%至64.71%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1399198.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"宣泰医药(688247.SH)发预减，预计2025年归母净利润4507万元至5408万元，同比下降57.65%至64.71%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688247"],"gpt_icon":0},{"id":"2602536749","title":"每周股票复盘：宣泰医药（688247）注射用硫酸艾沙康唑获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2602536749","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602536749?lang=zh_cn&edition=full","pubTime":"2026-01-11 04:23","pubTimestamp":1768076586,"startTime":"0","endTime":"0","summary":"截至2026年1月9日收盘，宣泰医药报收于10.29元，较上周的9.7元上涨6.08%。本周，宣泰医药1月9日盘中最高价报10.31元。该药品适用于治疗成人侵袭性曲霉病和侵袭性毛霉病，注册分类为化学药品4类，上市许可持有人为公司本身。原研产品由辉瑞开发，已于2022年6月在国内获批并纳入医保乙类目录。2024年全年及2025年上半年销售额分别为2.04亿元和1.72亿元。此次获批有助于丰富公司产品线，提升竞争力，但销售情况受市场环境等因素影响存在不确定性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011100001474.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688247","BK0239"],"gpt_icon":0},{"id":"2601586480","title":"宣泰医药(688247.SH)：注射用硫酸艾沙康唑获得国家药品监督管理局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2601586480","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601586480?lang=zh_cn&edition=full","pubTime":"2026-01-06 15:34","pubTimestamp":1767684853,"startTime":"0","endTime":"0","summary":"智通财经APP讯，宣泰医药(688247.SH)发布公告，近日，公司收到国家药品监督管理局(简称“国家药监局”)核准签发的《药品注册证书》，批准公司注射用硫酸艾沙康唑上市。注射用硫酸艾沙康唑适用于治疗成人患者下列感染：侵袭性曲霉病，侵袭性毛霉病。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1389244.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"宣泰医药(688247.SH)：注射用硫酸艾沙康唑获得国家药品监督管理局批准","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688247","BK0239"],"gpt_icon":0},{"id":"2594711231","title":"宣泰医药(688247.SH)拟推2025年限制性股票激励计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2594711231","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594711231?lang=zh_cn&edition=full","pubTime":"2025-12-25 20:01","pubTimestamp":1766664079,"startTime":"0","endTime":"0","summary":"智通财经APP讯，宣泰医药(688247.SH)发布2025年限制性股票激励计划(草案)，拟向激励对象授予不超过623万股，约占激励计划草案公告时公司股本总额的1.37%。其中，首次授予不超过498.80万股，首次授予的激励对象不超过64人，授予价格为5.71元/股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1385884.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688247","BK0239"],"gpt_icon":0},{"id":"2590502931","title":"宣泰医药（688247）披露募投项目延期公告，12月12日股价下跌0.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590502931","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590502931?lang=zh_cn&edition=full","pubTime":"2025-12-12 22:30","pubTimestamp":1765549854,"startTime":"0","endTime":"0","summary":"截至2025年12月12日收盘，宣泰医药报收于10.0元，较前一交易日下跌0.5%，最新总市值为45.33亿元。该股当日开盘10.12元，最高10.12元，最低9.98元，成交额达1858.94万元，换手率为0.41%。近日，上海宣泰医药科技股份有限公司发布公告称，公司于2025年12月12日召开董事会，审议通过《关于募投项目延期的议案》，决定将“高端仿制药和改良型新药研发项目”达到预定可使用状态的时间由2025年12月延期至2027年12月。保荐机构对本次延期无异议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121200042008.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688247"],"gpt_icon":0},{"id":"2589117359","title":"宣泰医药（688247）披露公司产品续约纳入国家医保目录，12月08日股价上涨0.39%","url":"https://stock-news.laohu8.com/highlight/detail?id=2589117359","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589117359?lang=zh_cn&edition=full","pubTime":"2025-12-08 22:24","pubTimestamp":1765203880,"startTime":"0","endTime":"0","summary":"截至2025年12月8日收盘，宣泰医药报收于10.37元，较前一交易日上涨0.39%，最新总市值为47.01亿元。该股当日开盘10.36元，最高10.4元，最低10.3元，成交额达1844.61万元，换手率为0.39%。近日，上海宣泰医药科技股份有限公司发布公告，其产品西格列汀二甲双胍缓释片以国谈续约形式纳入《国家基本医疗保险、生育保险和工伤保险药品目录》，医保支付标准维持3.47元/片不变，协议有效期为2026年1月1日至2027年12月31日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120800035182.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688247","BK0239"],"gpt_icon":0},{"id":"2586258562","title":"11月26日宣泰医药现346.5万元大宗交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2586258562","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586258562?lang=zh_cn&edition=full","pubTime":"2025-11-26 17:52","pubTimestamp":1764150766,"startTime":"0","endTime":"0","summary":"证券之星消息，11月26日宣泰医药发生大宗交易，交易数据如下：大宗交易成交价格10.5元，成交33万股，成交金额346.5万元，买方营业部为民生证券股份有限公司苏州分公司，卖方营业部为广发证券股份有限公司总部。近三个月该股共发生1笔大宗交易，合计成交3300.0手。该股在过去半年内已有共计3.11亿股限售解禁股上市，占公司总股本的68.61%。截至2025年11月26日收盘，宣泰医药报收于10.5元，上涨0.19%，换手率1.08%，成交量4.88万手，成交额5200.03万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112600027282.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688247"],"gpt_icon":0},{"id":"2582554864","title":"每周股票复盘：宣泰医药（688247）股东减持8.7万股至持股4.98%","url":"https://stock-news.laohu8.com/highlight/detail?id=2582554864","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582554864?lang=zh_cn&edition=full","pubTime":"2025-11-09 04:54","pubTimestamp":1762635250,"startTime":"0","endTime":"0","summary":"截至2025年11月7日收盘，宣泰医药报收于10.73元，较上周的10.98元下跌2.28%。期间股价下跌0.09%，截至11月4日收盘价为10.86元。原减持计划拟减持不超过700万股，实际减持321.8万股，计划已实施完毕。自2025年8月5日至11月4日，其通过集中竞价减持3,218,000股，占总股本0.7098%。减持完成后持股比例降至4.9808%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110900001756.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688247"],"gpt_icon":0},{"id":"2580781580","title":"11月4日宣泰医药发布公告，股东减持8.7万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2580781580","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580781580?lang=zh_cn&edition=full","pubTime":"2025-11-04 18:01","pubTimestamp":1762250509,"startTime":"0","endTime":"0","summary":"证券之星消息，11月4日宣泰医药发布公告《宣泰医药:关于持股5%以上股东减持计划时间届满暨减持股份结果公告》，其股东南京市栖和创业投资合伙企业(有限合伙)于2025年10月23日至2025年11月4日间合计减持8.7万股，占公司目前总股本的0.0192%，变动期间该股股价下跌0.09%，截止11月4日收盘报10.86元。股东增减持详情见下表：根据宣泰医药2025年三季报公布的十大股东详情如下：以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110400029077.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688247","BK0239"],"gpt_icon":0},{"id":"2579183791","title":"宣泰医药(688247)9月30日股东户数0.78万户，较上期减少3.25%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579183791","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579183791?lang=zh_cn&edition=full","pubTime":"2025-10-30 17:28","pubTimestamp":1761816517,"startTime":"0","endTime":"0","summary":"证券之星消息，近日宣泰医药披露，截至2025年9月30日公司股东户数为7759.0户，较6月30日减少261.0户，减幅为3.25%。在化学制药行业个股中，宣泰医药股东户数低于行业平均水平，截至9月30日，化学制药行业平均股东户数为3.43万户。从股价来看，2025年6月30日至2025年9月30日，宣泰医药区间涨幅为5.71%，在此期间股东户数减少261.0户，减幅为3.25%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103000033143.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688247"],"gpt_icon":0},{"id":"2579118194","title":"宣泰医药(688247.SH)发布前三季度业绩，归母净利润6346万元，同比下降31.45%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579118194","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579118194?lang=zh_cn&edition=full","pubTime":"2025-10-30 16:29","pubTimestamp":1761812967,"startTime":"0","endTime":"0","summary":"智通财经APP讯，宣泰医药(688247.SH)披露2025年第三季度报告，公司前三季度实现营收3.31亿元，同比下降8.59%;归母净利润6346万元，同比下降31.45%;扣非净利润5388万元，同比下降36.64%;基本每股收益0.14元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1362696.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"宣泰医药(688247.SH)发布前三季度业绩，归母净利润6346万元，同比下降31.45%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688247"],"gpt_icon":0},{"id":"2579092205","title":"宣泰医药最新公告：奥拉帕利片拟中选第十一批全国药品集中采购","url":"https://stock-news.laohu8.com/highlight/detail?id=2579092205","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579092205?lang=zh_cn&edition=full","pubTime":"2025-10-29 16:48","pubTimestamp":1761727687,"startTime":"0","endTime":"0","summary":"宣泰医药(688247.SH)公告称，公司参与了国家组织药品联合采购办公室组织的第十一批全国药品集中采购的投标，根据联采办于2025年10月28日发布的《全国药品集中采购拟中选结果公示》显示，公司产品奥拉帕利片拟中选本次集中采购。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102900033931.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688247","BK0239"],"gpt_icon":0},{"id":"2577736588","title":"10月22日宣泰医药发布公告，股东减持313.1万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2577736588","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577736588?lang=zh_cn&edition=full","pubTime":"2025-10-22 19:01","pubTimestamp":1761130884,"startTime":"0","endTime":"0","summary":"证券之星消息，10月22日宣泰医药发布公告《宣泰医药:关于持股5%以上股东减持至5%的权益变动提示性公告》，其股东南京市栖和创业投资合伙企业(有限合伙)于2025年8月5日至2025年10月22日间合计减持313.1万股，占公司目前总股本的0.6907%，变动期间该股股价下跌12.97%，截止10月22日收盘报10.87元。股东增减持详情见下表：根据宣泰医药2025年中报公布的十大股东详情如下：以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102200031505.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688247"],"gpt_icon":0},{"id":"2577828782","title":"宣泰医药（688247）披露关于变更签字注册会计师的公告，10月21日股价上涨2.86%","url":"https://stock-news.laohu8.com/highlight/detail?id=2577828782","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577828782?lang=zh_cn&edition=full","pubTime":"2025-10-21 17:23","pubTimestamp":1761038599,"startTime":"0","endTime":"0","summary":"截至2025年10月21日收盘，宣泰医药报收于10.78元，较前一交易日上涨2.86%，最新总市值为48.87亿元。该股当日开盘10.54元，最高10.78元，最低10.5元，成交额达3107.74万元，换手率为0.64%。近日，宣泰医药发布关于变更签字注册会计师的公告。时英浩1996年成为注册会计师，1994年开始从事上市公司审计；缪雪2023年成为注册会计师，2021年开始从事上市公司审计。本次变更不会对公司2025年度审计工作产生不利影响。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102100026745.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688247","BK0239"],"gpt_icon":0},{"id":"2576119839","title":"宣泰医药(688247.SH)：西格列汀二甲双胍缓释片获美国FDA批准文号","url":"https://stock-news.laohu8.com/highlight/detail?id=2576119839","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2576119839?lang=zh_cn&edition=full","pubTime":"2025-10-20 16:18","pubTimestamp":1760948300,"startTime":"0","endTime":"0","summary":"智通财经APP讯，宣泰医药(688247.SH)公告，公司收到美国食品药品监督管理局(“FDA”)的通知，公司向美国FDA申报的西格列汀二甲双胍缓释片的简略新药申请(简称“ANDA””，即美国仿制药申请)获得暂时批准。西格列汀二甲双胍缓释片由MERCK SHARPDOHME公司开发，于2012年2月在美国获批上市，适用于改善成人2型糖尿病患者的血糖控制。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1357027.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"宣泰医药(688247.SH)：西格列汀二甲双胍缓释片获美国FDA批准文号","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688247","BK0239"],"gpt_icon":0},{"id":"2576041595","title":"每周股票复盘：宣泰医药（688247）每股派息0.025元（含税）","url":"https://stock-news.laohu8.com/highlight/detail?id=2576041595","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2576041595?lang=zh_cn&edition=full","pubTime":"2025-10-19 04:18","pubTimestamp":1760818689,"startTime":"0","endTime":"0","summary":"截至2025年10月17日收盘，宣泰医药报收于10.47元，较上周的10.74元下跌2.51%。本周，宣泰医药10月16日盘中最高价报10.83元。本周关注点公司公告汇总：宣泰医药2025年半年度每股派发现金红利0.025元（含税），股权登记日为2025年10月20日。国泰海通证券股份有限公司作为保荐机构，对上海宣泰医药科技股份有限公司2025年半年度利润分配涉及的差异化分红事项出具核查意见。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101900000888.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688247"],"gpt_icon":0},{"id":"2576064000","title":"宣泰医药公布国际专利申请：“恩扎卢胺药物组合物及其制备方法和用途”","url":"https://stock-news.laohu8.com/highlight/detail?id=2576064000","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2576064000?lang=zh_cn&edition=full","pubTime":"2025-10-18 05:19","pubTimestamp":1760735971,"startTime":"0","endTime":"0","summary":"证券之星消息，根据企查查数据显示宣泰医药（688247）公布了一项国际专利申请，专利名为“恩扎卢胺药物组合物及其制备方法和用途”，专利申请号为PCT/CN2025/087109，国际公布日为2025年10月16日。专利详情如下：图片来源：世界知识产权组织（WIPO）今年以来宣泰医药已公布的国际专利申请1个。结合公司2025年中报财务数据，今年上半年公司在研发方面投入了2570.4万元，同比减24.54%。数据来源：企查查以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101800003723.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688247","BK0239"],"gpt_icon":0},{"id":"2575321428","title":"宣泰医药（688247）披露2025年半年度权益分派实施公告，10月14日股价下跌0.96%","url":"https://stock-news.laohu8.com/highlight/detail?id=2575321428","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2575321428?lang=zh_cn&edition=full","pubTime":"2025-10-14 22:49","pubTimestamp":1760453356,"startTime":"0","endTime":"0","summary":"截至2025年10月14日收盘，宣泰医药报收于10.36元，较前一交易日下跌0.96%，最新总市值为46.97亿元。该股当日开盘10.49元，最高10.59元，最低10.35元，成交额达3414.57万元，换手率为0.72%。近日，宣泰医药发布2025年半年度权益分派实施公告。根据公告，本次利润分配方案为每股现金红利0.025元（含税），股权登记日为2025年10月20日，除权（息）日和现金红利发放日均为2025年10月21日。现金红利将由中登上海分公司进行派发，部分股东由公司自行发放。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101400065714.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688247","BK0239"],"gpt_icon":0},{"id":"2574127104","title":"宣泰医药（688247）股东南京市栖和创业投资合伙企业(有限合伙)质押1000万股，占总股本2.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2574127104","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2574127104?lang=zh_cn&edition=full","pubTime":"2025-10-10 18:37","pubTimestamp":1760092631,"startTime":"0","endTime":"0","summary":"证券之星消息，宣泰医药10月10日公开信息显示，股东南京市栖和创业投资合伙企业向深圳市高新投融资担保有限公司合计质押1000.0万股，占总股本2.21%。质押详情见下表：截止本公告日，股东南京市栖和创业投资合伙企业已累计质押股份2200.0万股，占其持股总数的85.28%。宣泰医药主营业务：自主实现高技术壁垒的仿制药的研发、产品注册申报、生产与销售;同时依托高标准的研发技术及产业化平台,为国内外新药企业及研发机构提供CRO/CMO服务。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101000030777.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688247","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1770603768465,"stockEarnings":[{"period":"1week","weight":0.0136},{"period":"1month","weight":0.0348},{"period":"3month","weight":-0.0298},{"period":"6month","weight":-0.1326},{"period":"1year","weight":0.0099},{"period":"ytd","weight":0.0732}],"compareEarnings":[{"period":"1week","weight":-0.0127},{"period":"1month","weight":-0.0049},{"period":"3month","weight":0.017},{"period":"6month","weight":0.1184},{"period":"1year","weight":0.243},{"period":"ytd","weight":0.0244}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"上海宣泰医药科技股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"7759人(较上一季度减少3.25%)","perCapita":"58427股","listingDate":"2022-08-25","address":"上海市浦东新区中国(上海)自由贸易试验区蔡伦路780号7层709室","registeredCapital":"45334万元","survey":" 上海宣泰医药科技股份有限公司的主营业务是高端仿制药研发与产业化及创新药CRO/CMO一体化服务。公司的主要产品是泊沙康唑肠溶片、美沙拉秦肠溶缓释片、马昔腾坦片、西格列汀二甲双胍缓释片、达格列净二甲双胍缓释片。","listedPrice":9.37},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"宣泰医药(688247)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供宣泰医药(688247)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"宣泰医药,688247,宣泰医药股票,宣泰医药股票老虎,宣泰医药股票老虎国际,宣泰医药行情,宣泰医药股票行情,宣泰医药股价,宣泰医药股市,宣泰医药股票价格,宣泰医药股票交易,宣泰医药股票购买,宣泰医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"宣泰医药(688247)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供宣泰医药(688247)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}